Apogee Therapeutics, Inc. (APGE)
NASDAQ · Healthcare
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- —
- P/E ratio
- —
- EPS
- —
- Volume
- 916,253
- 52-week high
- —
- 52-week low
- —
- Open
- $134.06
- Day high
- $134.24
- Day low
- $134.01
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | — | -$255.84M | -$4.22 |
| 2024 | — | -$182.15M | -$3.30 |
| 2023 | — | -$83.99M | -$3.36 |
| 2022 | — | -$39.79M | -$16.16 |
About Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
- CEO
- Michael Thomas Henderson
- Employees
- 196
- Country
- US
- IPO date
- Jul 14, 2023
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Apogee Therapeutics, Inc.'s stock price today?
- APGE is trading at $134.15 as of Jul 20, 2026.
- Does Apogee Therapeutics, Inc. pay a dividend?
- Apogee Therapeutics, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Apogee Therapeutics, Inc. in?
- Apogee Therapeutics, Inc. operates in the Healthcare sector.